Congratulations to Dr. Bryant Poole whose leadership efforts on the Ferring PRONOUNCE study were recently recognized. UCA, who has been a part of the study since 2016, have recently completed recruitment for the study.   The study itself was a comparison between Degarelix (firmagon) and Lupron (leuprolide), 2 medications that UCA currently uses in our clinics for our prostate cancer patients.  The purpose of the study was to look at the cardiovascular safety of the medications in prostate cancer patients with previously diagnosed cardiovascular disease.  Thank you to our Research Department who work diligently on these studies. 

To read more about the study, please visit –https://clinicaltrials.gov/ct2/show/NCT02663908)